Chipmakers are still catching up to demand following severe supply chain bottlenecks created by the pandemic. But manufacturing plants that were planned last year will likely start producing chips in the coming months, helping to alleviate shortages for PC parts and other microchips, Su said.
“We’ve always gone through cycles of ups and downs, where demand has exceeded supply, or vice versa,” Su said at the Code Conference in Beverly Hills, California. “This time, it’s different.”
The improvements will be gradual as more manufacturing capacity becomes available, Su said.
An inexpensive anti-seizure medication markedly improves learning and memory and other cognitive functions in Alzheimer’s patients who have epileptic activity in their brains, according to a study published in the Sept. 27th issue of JAMA Neurology.
“This is a drug that’s used for epilepsy,” says Keith Vossel, MD, MSc, director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, and the principal investigator on the clinical trial. “We used it in this study for Alzheimer’s patients who had evidence of silent epileptic activity, which is seizure-like brain activity without the associated physical convulsions.”
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Early symptoms include short-term memory loss, decline in problem solving, word-finding difficulties, and trouble with spatial navigation. Among Alzheimer’s patients, an estimated 10–22% develop seizures, while an additional 22–54% exhibit silent epileptic activity.
A large, UK-based study of genetics and autism spectrum disorder (ASD) has been suspended, following criticism that it failed to properly consult the autism community about the goals of the research. Concerns about the study include fears that its data could potentially be misused by other researchers seeking to ‘cure’ or eradicate ASD.
Study aimed at collecting DNA from 10,000 people with autism and their families has drawn criticism for failing to consult the autism community.
Dr. Jennifer Garrison, PhD (http://garrisonlab.com/) is Assistant Professor, Buck Institute for Research on Aging, Founder & Faculty Director, Global Consortium for Reproductive Longevity & Equality (https://www.buckinstitute.org/gcrle/), Assistant Professor in Residence, Cellular and Molecular Pharmacology, UCSF and Adjunct Assistant Professor of Gerontology, USC Leonard Davis School of Gerontology.
Dr. Garrison’s lab is interested in understanding how neuropeptides (a large class of signaling molecules which are secreted from neurons and transmit messages within the brain and across the nervous system) regulate changes in normal and aging animals as well in understanding how they control behavior at both the cell biological and neural circuit level.
Dr. Garrison received her PhD from the University of California San Francisco in Chemistry and Chemical Biology in the laboratory of Dr. Jack Taunton, where she discovered the molecular target of a natural product and elucidated a novel mechanism by which small molecules can regulate protein biogenesis. As a postdoctoral fellow in Dr. Cori Bargmann’s lab at the Rockefeller University, she showed that the nematode C. elegans produces a neuropeptide that is an evolutionary precursor of the mammalian peptides vasopressin and oxytocin, and mapped a neural circuit by which this molecule, nematocin, modulates mating behavior.
Dr. Garrison was named an Alfred P. Sloan Research Fellow and received a Glenn Foundation Award for Research in Biological Mechanisms of Aging in 2,014 and a Next Generation Leader at the Allen Institute for Brain Science in 2015. Her work is funded by the NIH National Institute of General Medical Sciences, the Glenn Foundation for Medical Research, the Alfred P. Sloan Foundation, and the Larry L. Hillblom Foundation.
Dr. Scott Gottlieb, the former FDA commissioner under President Trump, tells CNN’s Pamela Brown that the current Delta variant surge of coronavirus will likely finish running its course by the Thanksgiving holiday this fall.
Epic has developed technology that serves as a digital vaccination verification by binding a person’s identity with their vaccination or lab results and displaying it via QR codes on a smartphone, Wisconsin State Journal reported Sept. 27.
Epic has rolled out technology that serves as a digital vaccination verification by binding a person’s identity with their vaccination or lab results and displaying it via QR codes on a smartphone, Wisconsin State Journalreported Sept. 27.
Seven things to know:
1. The new tech is currently live for 25 million patients, and 70 million to 80 million people will have access to it by the end of 2,022 Nick Frenzer, an Epic implementation executive, told the publication.
Ageing is inevitable, but what if everything we’ve come to believe about ageing is wrong and we’re able to choose our lifespans? What if ageing is a disease?
In this week’s #HealthyLongevity #webinar, Prof David Sinclair from Harvard Medical School shares a bold new theory for why we age. Prof Sinclair is also the author of “Lifespan, Why We Age – and Why We Don’t Have To” (https://lifespanbook.com/).
Register for upcoming webinar sessions at https://nus-sg.zoom.us/webinar/register/9516279955794/WN_JhWMZNz0QGOgNqxtSBYedw.
#NUSMedicine #webinarseries
– References: - Closing video source: https://www.youtube.com/watch?v=vIFEpwA9qVk.
Disclaimer: The opinions and advice expressed in this webinar are those of the speakers and do not represent the views and opinions of the organizers and National University of Singapore or any of its subsidiaries or affiliates. The information provided in this webinar is for general information purposes only as part of a general discussion on public health. The information is not intended to be a substitute for professional medical advice, diagnoses or treatment; and cannot be relied on in place of consultation with your licensed healthcare provider.
All Rights Reserved. All of the proceedings of this webinar, including the presentation of scientific papers, are intended for limited publication only, and all property rights in the material presented, including common-law copyright, are expressly reserved to the speaker or NUS. No statement or presentation made is to be regarded as dedicated to the public domain. Any sound reproduction, transcript or other use of the material presented at this course without the permission of the speaker or NUS is prohibited to the full extent of common-law copyright in such material.
To treat lymphoma in dogs, veterinarians have traditionally relied on chemotherapy drugs first designed for people.
Now, the FDA has approved a medication specifically designed to treat canine cancer — and the new approach to chemo drug development might end up helping humans.
Lymphoma in dogs: Lymphoma is a cancer that starts in the cells and tissues of the lymphatic system. It’s one of the most common cancers in dogs, accounting for up to 24% of all new cases and affecting up to 70,000 pets in the U.S. annually.
The FDA has approved a medication specifically designed to treat lymphoma in dogs, potentially helping extend the lives of thousands of pets.
